Notes

On November 25, the daily limit analysis of shuanglao pharmaceutical industry: longevity drug NMN, heparin and assisted reproduction concept hot state.
nmn nature

Shuangbailu pharmaceutical set off a wave, with a closing price of 10.42 yuan. The stock rose at 10:10, with a one-time opening capital of 44.076 million won, accounting for 0.5% of the circulating market value.
According to the capital flow data, the main capital of the day was 83.827 million won, the hot money was 85.2081 million won, and the retail capital was 46.2319 million won. The capital flow in the last five days is shown in the table below.
On the same day, the concept of longevity drug NMN, heparin and assisted reproduction increased by 3.97%, 2.4% and 2.14%.
The logic of stock investment is as follows.
2. The company's long-term injection of follicle hormone for assisted reproduction phase I clinical trial
3. The company's product contains sodium alkoxide injection, which has won the second prize of scientific and technological progress in Shandong Province.
In terms of financial status, the newspaper of shuanglao pharmaceutical in the third quarter of 2021 showed that the company's main revenue was 913 million won, an increase of 8.42% over the same period last year. The net profit attributable to the parent company was 436 million won, an increase of 43.76% over the same period last year. Excluding non net profit of 226 million yuan, an increase of 51.4% over the same period last year. In the third quarter of 2021, the company's main revenue in the first quarter was 289 million won, a decrease of 5.38% over the same period last year. The net profit attributable to the parent company in the first quarter was 134 million won, an increase of 26.25% over the same period last year. In the first quarter, 77.0015 million won was deducted instead of net profit, an increase of 20.73% over the same period last year. The debt ratio is 7.18%, the return on investment is 81.8386 million won, the financial cost is - 12.65 million won, and the gross profit margin is 84.71%.
According to the specific evaluation and analysis tools of securities, the good company of shuangluo Pharmaceutical (002038) is star 2.5, the good price is star 2.5, and the comprehensive evaluation grade is star 2.5. (rating range: Star 1 ~ 5, highest star 5)) the stock has no agency rating in the last 90 days. In the past three months, the net capital outflow was 66.2066 million won, the financing balance decreased, the securities lending outflow was 1.3825 million won, and the securities lending balance decreased.
My Website: https://www.esthelivsale.com/store